Dronedarone
Dronedarone, sold as Multaq, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug. The label read lists one use: lowering the chance of being admitted to hospital for atrial fibrillation, for patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The label says the mechanism of action is unknown and that the medicine has antiarrhythmic properties belonging to all four Vaughan-Williams classes. It carries a boxed warning: in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.
Also called Multaq
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 233698 (dronedarone); UNII JQZ1L091Y2 (exact: the openFDA record of the label lists it and RxNorm gives it for the ingredient); the label describes the hydrochloride salt (RxNorm 736680). MeSH descriptor D000077764 is Dronedarone; its record lists the pharmacological action Anti-Arrhythmia Agents and says dronedarone was indexed under amiodarone analogs and derivatives from 1999 to 2018. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic [EPC]). The label read is the Sanofi-Aventis U.S. LLC label for Multaq tablets, application NDA022425, effective 2025-05-29 in openFDA. This page records label indications, the class, the mechanism sentences and the boxed warning only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says the mechanism of action of dronedarone is unknown; it has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each to the clinical effect is unknown.
Claims and evidence
Context Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation
- Excluded
- None stated
The US label of Multaq (dronedarone tablets, Sanofi-Aventis U.S. LLC, application NDA022425; the version dated 2025-05-29 in openFDA) describes dronedarone as an antiarrhythmic drug. It lists reducing the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.
Applies to Recipient not specified Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. A second openFDA Multaq record from a repackager was not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], highlights sentence
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indication statement
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06).
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250529.
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with decompensated heart failure or permanent atrial fibrillation, as described in a US Multaq label boxed warning
- Recipient
- Recipient not specified
- Population
- Patients with symptomatic heart failure and recent decompensation requiring hospitalization, patients with NYHA class IV heart failure, and patients with permanent atrial fibrillation, as the boxed warning describes the risks. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure
- Patients with permanent atrial fibrillation
- Excluded
- None stated
The same US label carries a boxed warning on an increased risk of death, stroke and heart failure in patients with decompensated heart failure or permanent atrial fibrillation. It says that in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and that for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.
Applies to Recipient not specified Patients with decompensated heart failure or permanent atrial fibrillation, as described in a US Multaq label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the label's boxed warning statements of risk only. The warning also states two contraindications; those are the label's and are not repeated as advice. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].boxed_warning[0], first paragraph, heart failure
- How it applies
- Label passage quoted in the research quote table (LB-09).
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph, permanent atrial fibrillation
- How it applies
- Label passage quoted in the research quote table (LB-10).
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250529.
- Retrieved
- Source effective date
- 2025-05-29
- Source state
- Current
- Version fingerprint
54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists reducing the risk of hospitalization for atrial fibrillation, in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq
The US label of Multaq (dronedarone tablets, Sanofi-Aventis U.S. LLC, application NDA022425; the version dated 2025-05-29 in openFDA) describes dronedarone as an antiarrhythmic drug. It lists reducing the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. A second openFDA Multaq record from a repackager was not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:dronedarone- Content hash
cd5dbb65968ef550f8a45a68f369cb85b500d1cc25ad9e00884c1372438c1798